1. KN026 (anti-HER2 bispecific antibody) in patients with previously treated, advanced HER2-expressing gastric or gastroesophageal junction cancer.
- Author
-
Xu, Jianming, Ying, Jieer, Liu, Rongrui, Wu, Jun, Ye, Feng, Xu, Nong, Zhang, Yanqiao, Zhao, Rusen, Xiang, Xiaojun, Wang, Jianhong, Lin, Xiaoyan, Xu, Huiting, Gao, Shegan, Luo, Suxia, Guo, Baohong, Li, Xionghui, Su, Yangzhi, and Wang, Qian
- Subjects
- *
THERAPEUTIC use of monoclonal antibodies , *THERAPEUTIC use of antineoplastic agents , *STOMACH tumors , *DRUG efficacy , *CLINICAL trials , *CONFIDENCE intervals , *EPIDERMAL growth factor receptors , *ONCOGENES , *MONOCLONAL antibodies , *ANTINEOPLASTIC agents , *GENE expression , *DESCRIPTIVE statistics , *ESOPHAGEAL tumors , *PATIENT safety , *EVALUATION - Abstract
KN026 is a novel human epidermal growth factor receptor 2 (HER2)-targeted bispecific antibody that binds two distinct domains of HER2. We report the safety and efficacy results of the phase 2 trial in patients with advanced HER2-expressing gastric or gastroesophageal junction cancer who failed from at least one prior line of standard treatment. In this open-label, multicentre, phase 2 trial, eligible patients were enrolled in the high-level HER2 cohort or low-level HER2 cohort and assigned to receive KN026 10 mg/kg (once a week), 20 mg/kg (once every two weeks) or 30 mg/kg (once every three weeks) intravenously. The primary end-points were the objective response rate (ORR) and duration of response assessed according to Response Evaluation Criteria in Solid Tumours (version 1.1). Between 17th June 2019 and 23rd August 2021, 45 patients were enrolled and received at least one dose of KN026, including 27 patients in the high-level HER2 cohort, 14 patients in the low-level HER2 cohort and four patients who had no HER2 expression. The ORR in the high-level HER2 cohort was 56% (95% confidence interval [CI] 35%–76%), with a durable response duration of 9.7 months (95% CI 4.2–not evaluable); while for the patients with low-level HER2, the ORR was 14% (95% CI 2%–43%). The most frequent ≥ grade 3 treatment-emergent adverse events were gastrointestinal disorders (five patients, 11%). No drug-related deaths were reported. KN026 showed a favourable safety profile and promising anti-tumour activity. Our results support further studies evaluating KN026 and the combination treatment with other active drugs in patients with advanced gastric or gastroesophageal junction cancer having high-level HER2 expression. • KN026, a new anti-human epidermal growth factor receptor 2 (HER2) bispecific antibody, binds HER2 domains II and IV. • KN026 improved the objective response rate as 2nd-line therapy in patients with HER2 high-level gastric/gastroesophageal junction cancer. • KN026 has a great potential to overcome Trastuzumab resistance. • KN026 demonstrated a favourable safety profile. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF